Synthetic carbohydrate-based vaccines: challenges and opportunities
R Mettu, CY Chen, CY Wu - Journal of Biomedical Science, 2020 - Springer
Glycoconjugate vaccines based on bacterial capsular polysaccharides (CPS) have been
extremely successful in preventing bacterial infections. The glycan antigens for the …
extremely successful in preventing bacterial infections. The glycan antigens for the …
Development in the concept of bacterial polysaccharide repeating unit-based antibacterial conjugate vaccines
R Rohokale, Z Guo - ACS infectious diseases, 2023 - ACS Publications
The surface of cells is coated with a dense layer of glycans, known as the cell glycocalyx.
The complex glycans in the glycocalyx are involved in various biological events, such as …
The complex glycans in the glycocalyx are involved in various biological events, such as …
Streptococcus pneumoniae serotype 19A: worldwide epidemiology
R Isturiz, HL Sings, B Hilton, A Arguedas… - Expert review of …, 2017 - Taylor & Francis
Introduction: Streptococcus pneumoniae causes mucosal and invasive diseases with high
morbidity and mortality. Introduction of the 7-valent pneumococcal conjugate vaccine …
morbidity and mortality. Introduction of the 7-valent pneumococcal conjugate vaccine …
Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised …
D Barug, I Pronk, MA van Houten… - The Lancet Infectious …, 2019 - thelancet.com
Background Maternal tetanus, diphtheria, and acellular pertussis (Tdap) vaccination offers
protection for neonates against clinical pertussis until primary vaccinations, but maternal …
protection for neonates against clinical pertussis until primary vaccinations, but maternal …
Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control …
Á Domínguez, P Ciruela, S Hernández… - PLoS …, 2017 - journals.plos.org
Background The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed based
on the results of immunogenicity studies and correlates of protection derived from …
on the results of immunogenicity studies and correlates of protection derived from …
Increased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in The …
M Vissers, AJ Wijmenga-Monsuur, MJ Knol, P Badoux… - PloS one, 2018 - journals.plos.org
The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in The Netherlands
in 2006 and was replaced by PHiD-CV10 in 2011. Data on carriage prevalence of S …
in 2006 and was replaced by PHiD-CV10 in 2011. Data on carriage prevalence of S …
[HTML][HTML] Quality of antibody responses by adults and young children to 13-valent pneumococcal conjugate vaccination and Streptococcus pneumoniae colonisation
Childhood pneumococcal conjugate vaccine (PCV) protects against invasive pneumococcal
disease caused by vaccine-serotype (VT) Streptococcus pneumoniae by generating …
disease caused by vaccine-serotype (VT) Streptococcus pneumoniae by generating …
Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised …
B Temple, NT Toan, VTT Dai, K Bright… - The Lancet Infectious …, 2019 - thelancet.com
Background Few data are available to support the choice between the two currently
available pneumococcal conjugate vaccines (PCVs), ten-valent PCV (PCV10) and 13-valent …
available pneumococcal conjugate vaccines (PCVs), ten-valent PCV (PCV10) and 13-valent …
Relationship between immune response to pneumococcal conjugate vaccines in infants and indirect protection after vaccine implementation
R Dagan - Expert Review of Vaccines, 2019 - Taylor & Francis
Introduction: Streptococcus pneumoniae is a leading cause of morbidity and mortality
worldwide. Widespread infant vaccination with pneumococcal conjugate vaccines (PCVs) …
worldwide. Widespread infant vaccination with pneumococcal conjugate vaccines (PCVs) …
[HTML][HTML] Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia—results of a phase …
E Clarke, AO Bashorun, M Okoye, A Umesi, MB Hydara… - Vaccine, 2020 - Elsevier
Background A more affordable pneumococcal conjugate vaccine (PCV) that provides
comparable protection to current PCVs is needed to ensure sustainable access in resource …
comparable protection to current PCVs is needed to ensure sustainable access in resource …